Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 81.86% | 83.15% | -357.07% | -278.03% | -437.61% |
| Total Depreciation and Amortization | -21.14% | -19.78% | -16.93% | -11.42% | -4.09% |
| Total Amortization of Deferred Charges | 264.39% | 321.91% | 304.28% | 166.22% | 88.57% |
| Total Other Non-Cash Items | -94.88% | -94.92% | 701.92% | 536.21% | 691.27% |
| Change in Net Operating Assets | -81.46% | 58.11% | 8,627.69% | 96.85% | 2.08% |
| Cash from Operations | -90.17% | 1.92% | 367.29% | 112.79% | -28.16% |
| Capital Expenditure | 0.73% | 53.38% | 52.42% | 65.02% | 28.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.42% | -188.59% | -146.54% | -150.24% | -155.43% |
| Cash from Investing | 0.40% | 0.11% | -38.62% | 10.78% | -102.85% |
| Total Debt Issued | 1,130.77% | 534.92% | 354.55% | -100.00% | -56.95% |
| Total Debt Repaid | -783.75% | -500.83% | -335.67% | 63.04% | 70.53% |
| Issuance of Common Stock | -31.98% | -46.03% | -87.63% | -51.29% | -45.85% |
| Repurchase of Common Stock | 75.21% | 81.65% | 72.96% | 71.05% | 72.17% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -494.28% | -1,221.38% | -2,280.12% | -326.71% | -- |
| Cash from Financing | 165.54% | 65.71% | -885.50% | -76.37% | 77.85% |
| Foreign Exchange rate Adjustments | -123.62% | 4.86% | 765.00% | 1,212.50% | 286.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.67% | 20.22% | 2,674.86% | 391.57% | 1,329.71% |